400 related articles for article (PubMed ID: 25399521)
1. Development of onabotulinumtoxinA for chronic migraine.
Whitcup SM; Turkel CC; DeGryse RE; Brin MF
Ann N Y Acad Sci; 2014 Nov; 1329():67-80. PubMed ID: 25399521
[TBL] [Abstract][Full Text] [Related]
2. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
3. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
[TBL] [Abstract][Full Text] [Related]
4. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
5. Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example.
Dodick DW; Turkel CC; DeGryse RE; Diener HC; Lipton RB; Aurora SK; Nolan ME; Silberstein SD
J Pain; 2015 Feb; 16(2):164-75. PubMed ID: 25464159
[TBL] [Abstract][Full Text] [Related]
6. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
Aurora SK; Dodick DW; Diener HC; DeGryse RE; Turkel CC; Lipton RB; Silberstein SD
Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
[TBL] [Abstract][Full Text] [Related]
7. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
Lipton RB; Varon SF; Grosberg B; McAllister PJ; Freitag F; Aurora SK; Dodick DW; Silberstein SD; Diener HC; DeGryse RE; Nolan ME; Turkel CC
Neurology; 2011 Oct; 77(15):1465-72. PubMed ID: 21956721
[TBL] [Abstract][Full Text] [Related]
8. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P;
J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917
[TBL] [Abstract][Full Text] [Related]
9. An academic debate: OnabotulinumtoxinA for chronic migraine: PREEMPT-derived vs "customized" dosing/injection paradigm.
Green MW; Rothrock JF
Toxicon; 2018 Jun; 147():116-119. PubMed ID: 29596847
[TBL] [Abstract][Full Text] [Related]
10. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
Negro A; Curto M; Lionetto L; Martelletti P
J Headache Pain; 2015; 17():1. PubMed ID: 26792662
[TBL] [Abstract][Full Text] [Related]
11. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
[TBL] [Abstract][Full Text] [Related]
12. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.
Dodick DW; Silberstein SD; Lipton RB; DeGryse RE; Adams AM; Diener HC
Cephalalgia; 2019 Jul; 39(8):945-956. PubMed ID: 31112399
[TBL] [Abstract][Full Text] [Related]
13. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data.
Davies B; Gaul C; Martelletti P; García-Moncó JC; Brown S
J Headache Pain; 2017 Sep; 18(1):93. PubMed ID: 28879545
[TBL] [Abstract][Full Text] [Related]
14. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
Blumenfeld AM; Stark RJ; Freeman MC; Orejudos A; Manack Adams A
J Headache Pain; 2018 Feb; 19(1):13. PubMed ID: 29404713
[TBL] [Abstract][Full Text] [Related]
15. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
16. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation.
Bendtsen L; Sacco S; Ashina M; Mitsikostas D; Ahmed F; Pozo-Rosich P; Martelletti P
J Headache Pain; 2018 Sep; 19(1):91. PubMed ID: 30259200
[TBL] [Abstract][Full Text] [Related]
17. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis.
Matharu M; Halker R; Pozo-Rosich P; DeGryse R; Manack Adams A; Aurora SK
J Headache Pain; 2017 Dec; 18(1):78. PubMed ID: 28766236
[TBL] [Abstract][Full Text] [Related]
18. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention.
Lipton RB; Silberstein SD
Headache; 2015 Mar; 55 Suppl 2():103-22; quiz 123-6. PubMed ID: 25662743
[TBL] [Abstract][Full Text] [Related]
19. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
Diener HC; Dodick DW; Aurora SK; Turkel CC; DeGryse RE; Lipton RB; Silberstein SD; Brin MF;
Cephalalgia; 2010 Jul; 30(7):804-14. PubMed ID: 20647171
[TBL] [Abstract][Full Text] [Related]
20. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.
Frampton JE
Drugs; 2012 Apr; 72(6):825-45. PubMed ID: 22468643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
